

DECEMBER 14-15, 2017

Stephenson CANCER CENTER

END CANCER

*Emerging Nanotechnology &
Drug Delivery Applications for Cancer*

ACKNOWLEDGEMENTS

Funding support by the Stephenson Cancer Center, the Symposium Grant from the Presbyterian Health Foundation, and The University of Oklahoma Health Sciences, Department of Pathology.



INTERNET CONNECTION:

OUHSC Guest

WELCOME LETTER

Funding support by the Stephenson Cancer Center, the Symposium Grant from the Presbyterian Health Foundation, and The University of Oklahoma Health Sciences, Department of Pathology. Nust, optas aditas exerorpore pelesedi nusapic idessen digenih ilist, sit explicto omnihic tincimus sam, santus atia atet eos vent autemporrurum solestisquo cus cuptasi dunt vellor arum nesto officitiorro blab ipis simoditae. Ut apiendis ra dignatur, od quaturia qui ut rem sunt veliquo odis anitibus eossed utat evel

invellest, occum que nonectur, samusae et, quas ipsunti verum, simi, tesedis pa sedita eiunte et utem experovit ra que nobita nam, volupta temperi assectatur? Antempo repedis alitiur assed unt.

Et im eos dem il excea qui utatus, velent esti ut asperferro corem invendit hitem exceptati cor resequi consequi quiam dolendit, officitem quuntot atusantia corroidus aut pernam nis verro dit est, volorem labor re nistem soluptatecto quatem sunt fugitis simusti od magnat excero eum aut re dolor accum voluptae vent voluptatis is molupta temquam faccabore vendis eum ipicipiet autatur sectamet

quiam il illorporum nonsend itatur, voluptaquo omnis utemquid ma natecab orporia et aut aut et fuga. Odicia dolorep erorem. Nem etur sintotat volut laborroid quae num fugiaturem reic te eium facescipis aut hari doluptium in plat quas simi, ium ium fuga. Nam lanitius et volorit eatio volupta tendae nonestotas vendae estrum sus estiunt uriberum dolupta dolupta tiamuscus et aboribus ma sam

doloreium veliquis molesectur re rerum none perio voles sin plitium aliquat enihil eos sit fugia volupta nos nonsequatem verior sant pratem nonsequiae occusda ntiusae iusam, qui accatquam, tem ratur? Ape pra sin estem ipis conserum cus iumquiamusti ab incit dendit harum repta aspe esti sit, sectae. Tur am eius, omnimaximus volupta temporum re volorerum ernam, cori cuptatu ressitaequi sit laborepudio

DR. RAMESH

Endiandit Res Destiandae

TABLE OF CONTENTS

05

ORGANIZING COMMITTEE

06

AGENDA AT A GLANCE

08

DETAILED AGENDA

10

PRESENTATIONS

13

KEYNOTE ADDRESS

Omid Farokhzad, MD, MBA

15

SESSION I

Nucleic Acids Origami

18

SESSION II

Molecular & Diagnostic Imaging

22

SESSION III

Drug Delivery

24

SESSION IV

Cancer Gene & Drug Therapy

28

KEYNOTE ADDRESS

Piotr Grodzinski, PhD

32

KEYNOTE ADDRESS

Xiaoyuan (Shawn) Chen, PhD

36

SESSION V

Nanotechnology & Tumor Microenvironment

37

SESSION VI

Theranostics

38

SESSION VII

Photonics & Photodynamic Therapy

39

SESSION VIII

Novel Technologies & Applications in Cancer

40

POSTERS

ORGANIZING COMMITTEE

CHAIRMAN

RAJAGOPAL RAMESH, PHD

*Professor, Department of Pathology
Co-Leader, Pre-Clinical Translational Research Program
Project Co-Leader, Nanomedicine Program
Jim & Christy Everest Endowed Chair in Cancer
Developmental Therapeutics
Oklahoma TSET Cancer Research Scholar
Stephenson Cancer Center
The University of Oklahoma Health Sciences Center*

COORDINATORS

CLAIRE TURMELLE

*Director, Marketing &
Communications
Stephenson Cancer Center
The University of Oklahoma
Health Sciences Center*

STEVIE WARNER, MHR

*Project Manager
Stephenson Cancer Center
The University of Oklahoma
Health Sciences Center*

MEMBERS

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

HANDAN ACAR, PHD

*Assistant Professor
Stephenson School of Biomedical
Engineering
The University of Oklahoma*

DETAILED AGENDA

THURSDAY, DECEMBER 14, 2017

7AM TO 8AM

Registration / Breakfast

Samis Education Center, Level 2

Meet the Investigators Session –

Students & Post-Doctoral Fellow

(Advanced Registration Required)

Andrews Academic Tower,

Conference Room

8AM TO 5PM


Poster Display

Samis Education Center, Level 1

DETAILED AGENDA

KEYNOTE ADDRESS

OMID C. FAROKHZAD, MD, MBA



*Professor of Anesthesia
Harvard Medical School
Center for Nanomedicine
Department of Anesthesiology, Perioperative and Pain Medicine
Brigham and Women's Hospital
OFarokhzad@bwh.harvard.edu*

Omid Farokhzad is a Professor at Harvard Medical School (HMS) and a physician-scientist in the Department of Anesthesiology at Brigham and Women's Hospital (BWH). Dr. Farokhzad established and directs the Center for Nanomedicine at BWH. He is a faculty member of the Brigham Research Institute Cancer Research Center. He is additionally a member of the Dana Farber/Harvard Cancer Center. Dr. Farokhzad's research is focused on the development of therapeutic nanoparticle technologies; most notably, he pioneered the high throughput combinatorial development and screening of multifunctional nanoparticles for medical applications. Dr. Farokhzad has authored approximately 140 papers (>32,018 citations; H-Index 73) and is an inventor of more than 145 issued / pending patents. The technologies that Dr. Farokhzad has developed with collaborators at HMS and MIT formed the basis for the launch of four biotechnology companies: BIND Therapeutics (NASDAQ: BIND; acquired by Pfizer), Selecta Biosciences (NASDAQ: SELB), Tarveda Therapeutics (formerly Blend Therapeutics) and Placon Therapeutics (formerly Blend Therapeutics), which are translating the aforementioned academic innovations toward commercialization and societal impact. Dr. Farokhzad has served in various capacities on the Board of Directors and the Scientific Advisory Board of these companies. He was a recipient of the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes, for the development and industrialization of nanoparticle technologies for medical applications. In 2014, he received the Golden Door Award from the International Institute of New England for his societal and economic impact as a naturalized USA citizen. In 2015, he was named as one of The Worldview 100 by Scientific American, which recognized visionaries who shape biotechnology around the world. In 2016, he was among the recipients of the Ellis Island Medal of Honor for his scientific, societal and economic contributions to America as an immigrant. Dr. Farokhzad was elected to the College of the Fellows of the American Institute of Medical and Biological Engineering. He was selected by Thomson Reuters among the Highly Cited Researchers in 2014, 2015 and 2016. The Boston Globe selected him among the top innovators in Massachusetts and the Boston Business Journal selected him among the Health Care Champions for his innovations. In 2012, he was among the regional Ernst & Young Entrepreneur of the Year awardees. Dr. Farokhzad completed his post-graduate clinical and post-doctoral research trainings, respectively, at the BWH/HMS and MIT in the laboratory of Institute Professor Robert Langer. He received his M.D. and M.A. from Boston University School of Medicine and his M.B.A. from the MIT Sloan School of Management.

KEYNOTE ADDRESS

KEYNOTE ADDRESS

KEYNOTE ADDRESS

KEYNOTE ADDRESS

KEYNOTE ADDRESS

KEYNOTE ADDRESS

KEYNOTE ADDRESS